Treprostinil phosphate
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- Treprostinil phosphate
- Molecular weight
- 550.48
- Structure (SMILES)
- CCCCC[C@@H](CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1OP(=O)(O)O)OP(=O)(O)O
- treprostinil bisphosphate
- Treprostinil bisphosphate
- treprostinil phosphate
- Treprostinil phosphate
- TREPROSTINIL PHOSPHATE [USAN]
- treprostinil phosphate usan
- ut 86
- UT-86
- CAS registry numbers
- 830354-49-9
- ChEMBL ID
- CHEMBL5314603
- InChIKey
- IERCXWVEMYXPMR-KSSXRGRSSA-N
- PubChem compound IDs
- 156104640
- FDA ingredient codes (UNII)
- 99S2PY5BN2
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -prost-
Investigated indications
- Condition
- Pulmonary Arterial Hypertension
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001361
- Subject identifier
- D000081029
- Condition identifier
- EFO_0001361
- Condition identifier
- MONDO_0015924
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 5
- Polar surface area
- 180.05
- Calculated partition coefficient (ALogP)
- 3.82
- Calculated partition coefficient (XLogP)
- 2.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 14
- Heavy atoms
- 36
- Molecular formula
- C23H36O11P2
- Monoisotopic mass
- 550.17328596
- Natural product
- No
Related records
Trials (25)
- A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
- A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
- An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
- Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
- Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain
- Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
- Inhaled Treprostinil for PAH: Open-label Extension
- Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
- Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
- Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
- Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
- Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension
- Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso
- Remodulin® to Oral Treprostinil Transition
- Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
- Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
- Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
- Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
In development for (1)
- Pulmonary arterial hypertension Phase 1